Semaglutide Online review

The service supports a comparison of oral and injected compounded plans, but the written purchase terms need clarification. Use the actual monthly or plan-total price and obtain payment, renewal, cancellation and refund rules for the chosen option before paying.

The legal page identifies US Health and Wellness, Inc. as the platform operator and describes independent clinicians connected through FitLink. It disclaims directly providing medical or pharmacy services. A distinct named treating practice, clinician roster and dispensing compounding pharmacy are not established, so request those identities before beginning care.

The legal contact details contain unresolved inconsistencies, including a Las Vegas, Nevada address paired with a mismatched ZIP code and an incomplete jurisdiction clause. These details do not establish where the treating practice operates. Ask for the correct legal counterparty and applicable purchase terms rather than relying on the contact block alone.

The service offers an online intake followed by clinical review and conditional prescribing. Its estimated review within twelve hours and shipping within two to four business days are advertised expectations, rather than guaranteed timing. The homepage describes partner-pharmacy delivery for compounds and a pharmacy of choice for branded prescriptions.

The program describes adult weight-management assessment, including BMI of thirty or higher, or twenty-seven or higher with a related condition, and review for contraindications. The terms require eighteen or the higher local age of majority. Eligibility wording on the tirzepatide page also refers to semaglutide, so ask the clinician which criteria apply to the actual treatment.

Alabama is explicitly unavailable. The site says it checks state law for each applicant and describes treatment in most states, without a complete current roster. The terms require the patient’s location to match the shipping state. Availability elsewhere should be confirmed for the specific product rather than inferred from that general reach claim.

The oral semaglutide and both tirzepatide multi-month cards explicitly describe three or five monthly shipments. The semaglutide injection cards identify three- or five-month prescription subscriptions without separately establishing shipment cadence. Plan duration, shipment frequency and payment schedule therefore need separate confirmation.

The privacy policy covers identifiers, treatment requests, medical history and payments. It permits disclosures to clinical providers and service vendors, as well as limited information to advertising platforms. A separate notice for the treating medical practice is not established. Request that notice and clarify which information reaches marketing services before submitting sensitive details.

Both compounded semaglutide injection and oral product cards list $219 for a month-to-month subscription or $229 for one month without a subscription. Their three-month plan total is $597, averaging $199 per month; the five-month total is $895, averaging $179 per month. Medication, provider review and shipping are listed as included. The lower averages are not the $219 monthly subscription.

Both compounded tirzepatide injection and oral cards list $349 for month-to-month subscription or $359 for one month without subscription. The three-month total is $957, averaging $319 per month, and the five-month total is $1,495, averaging $299 per month. Those cards also include medication, provider review and shipping.

The homepage promotes semaglutide at $179 per month in one place and $199 per month in detailed text and FAQs, while the general tirzepatide headline is $299 per month. The specific product cards associate those lower figures with multi-month averages. Compare the chosen plan’s total and duration rather than assuming a low headline is available without a longer commitment.

The cards label multi-month totals but do not establish exactly when that amount is charged, whether those plans automatically renew or the authorization cutoff. Monthly cards identify recurring subscriptions, but precise renewal dates and cancellation deadlines remain unclear. Financing repayments over twelve or twenty-four months are separate debt payments, not the monthly cost or duration of treatment.

Branded pathways are priced differently: advertised medication charges are $149 for a Wegovy pill, $199 for Wegovy or Ozempic injection, and $299 for Zepbound, each plus $44 per month for provider care. These are conditional advertised scenarios, with dose, pharmacy price, benefit and savings restrictions unresolved. The service’s pricing and regulatory claims are not independently validated, and these amounts should not be treated as guaranteed all-patient offers.

The site discusses commercial coverage and manufacturer savings while excluding Medicare, Medicaid and other government programs from those offers. No specific insurance billing arrangement or personal benefit is established. Confirm the branded medication price at the dispensing pharmacy separately from the $44 care subscription; compound product-card inclusions follow a different model.

Cancellation statements materially disagree. Some homepage and program FAQs promise cancellation anytime through the portal or coordinator, while another homepage FAQ says selected one-, two-, four- or six-month programs cannot be canceled after treatment starts. The actual product cards instead offer one-, three- and five-month plans. The transparency page also describes month-to-month access and no six-month upfront charge. These statements do not establish one reliable cancellation rule.

Refund promises also have different scopes. The homepage and program pages describe no charge or a full refund when no safe or appropriate treatment is available. A thirty-day satisfaction offer refunds evaluation fees only and excludes medication. The legal terms separately promise a full refund if a prescription is not fulfilled. None establishes a general medication money-back guarantee or a clear post-shipment allocation. Obtain the controlling policy for your plan in writing.

The program and product pages explicitly offer compounded semaglutide and tirzepatide in injection and oral forms. The semaglutide program calls its oral option drops; the exact oral tirzepatide dosage form is not established. Exact additives, concentrations and dose-specific quantities are also unresolved.

Compounded products are not FDA approved. The service’s references to pharmacies, testing or regulatory categories do not independently establish product equivalence, a pharmacy’s status or clinical suitability. Separately promoted Wegovy, Ozempic and Zepbound pathways should not be assumed to share the compounds’ pricing, delivery or product characteristics.